---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-033825"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2023-09-27T23:59:59+00:00"
generated_at: "2026-06-10T08:05:20.643605+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lixte appoints Bas van der Baan as President and CEO; founder Kovach becomes Executive Chairman

## Summary
- Bastiaan van der Baan named President, CEO and Vice Chairman effective September 26, 2023.
- Founder John S. Kovach, M.D. becomes Executive Chairman, remains Chief Scientific Officer.
- Employment agreement: 3-year term, $150,000 annual salary, with discretionary bonus.
- Granted options to purchase 250,000 shares at $1.95, vesting quarterly over 3 years.
- van der Baan brings 20+ years biotech experience; previously Chief Clinical Officer at Agendia.

## SEC filing metadata
- accession: 0001493152-23-033825
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2023-09-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000149315223033825/0001493152-23-033825-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000149315223033825/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-033825
- JSON: https://secwatch.observer/filing/0001493152-23-033825.json
- Plain text: https://secwatch.observer/filing/0001493152-23-033825.txt

## Key facts
- Executive change
  John S. Kovach was appointed as Executive Chairman at LIXTE BIOTECHNOLOGY HOLDINGS, INC..
  - Action: appointed
  - Role: Executive Chairman
  source text: Effective September 26, 2023, the Company appointed John S. Kovach, M.D. as Executive Chairman. Dr. Kovach will no longer act as the Company’s President and Chief Executive Officer, but will continue as the Company’s Chief Scientific Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1335105/000149315223033825/0001493152-23-033825-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.